Pronutria Biosciences Appoints Garry E. Menzel, Ph.D., as Chief Business and Strategy Officer

Pronutria Biosciences Appoints Garry E. Menzel, Ph.D., as Chief Business and Strategy Officer

October 19, 2015

Cambridge, Mass., October 19th, 2015 / BUSINESS WIRE / -- Pronutria Biosciences™ Inc., a biotechnology company pioneering a new class of therapeutics to mediate amino acid biology, announced today the appointment of Garry E. Menzel, Ph.D., as Chief Business and Strategy Officer.

Selecta Continues to Successfully Advance Pipeline of Novel Immunotherapeutic Candidates

Selecta Continues to Successfully Advance Pipeline of Novel Immunotherapeutic Candidates

October 16, 2015

Data related to Selecta’s targeted antigen-specific immune therapies presented at the American Society for Nanomedicine Annual Meeting

Novel therapies apply unique immune-modulating capabilities of Selecta’s Synthetic Vaccine Particle platform described in an article published in PNAS 

Agios Outlines Key Clinical Development & Research Strategies

Agios Outlines Key Clinical Development & Research Strategies

October 16, 2015

- Phase 3 Study of AG-221 in Relapsed/Refractory IDH2 Mutant Acute Myeloid Leukemia (IDHENTIFY) Initiated -

- Frontline Combination Development Strategy for AG-221 and AG-120 Announced -

- Second Pyruvate Kinase-R Activator AG-519 Entering Clinical Development -

- Company to Webcast Today's R&D Day -

Eleven Biotherapeutics Completes Enrollment in Pivotal Phase 3 Study of Isunakinra (EBI-005) in Patients with Allergic Conjunctivitis

Eleven Biotherapeutics Completes Enrollment in Pivotal Phase 3 Study of Isunakinra (EBI-005) in Patients with Allergic Conjunctivitis

October 15, 2015

-Eleven Granted Isunakinra as the International Nonproprietary Name for EBI-005-

Christopher A. Viehbacher Joins Pronutria Biosciences’ Board of Directors

Christopher A. Viehbacher Joins Pronutria Biosciences’ Board of Directors

October 15, 2015

Gurnet Point Capital Invests in Pronutria’s Series C Financing

BIND Therapeutics Expands Board of Directors with Appointment of Dr. Arthur Tzianabos

BIND Therapeutics Expands Board of Directors with Appointment of Dr. Arthur Tzianabos

October 14, 2015

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine company developing targeted and programmable therapeutics called AccurinsTM, today announced the appointment of Arthur Tzianabos, Ph.D., president and chief scientific officer of OvaScience, Inc., to the Company's board of directors.

Visterra’s Monoclonal Antibody in Development for the Treatment of Influenza A, VIS410, Demonstrated Significant Antiviral Activity and Reduced Duration of Respiratory Symptoms in Phase 2a Challenge Study

Visterra’s Monoclonal Antibody in Development for the Treatment of Influenza A, VIS410, Demonstrated Significant Antiviral Activity and Reduced Duration of Respiratory Symptoms in Phase 2a Challenge Study

October 5, 2015

– Study Achieved its Primary Endpoint of Reduction in Viral Shedding; Treatment with VIS410 Resulted in a 92% Reduction of Virus vs. Placebo –

– Study Results Support Further Development of VIS410 in Hospitalized Patients with Influenza A –

Visterra Awarded Contract Valued at up to $204.5 Million to Advance the Development of VIS410, its Novel Monoclonal Antibody for the Treatment of Influenza A, by the Biomedical Advanced Research and Development Authority (BARDA)

Visterra Awarded Contract Valued at up to $204.5 Million to Advance the Development of VIS410, its Novel Monoclonal Antibody for the Treatment of Influenza A, by the Biomedical Advanced Research and Development Authority (BARDA)

October 5, 2015

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Visterra, Inc., a clinical-stage biotechnology company that uses its proprietary technology platform to identify unique disease targets and design novel therapeutics for infectious diseases, today announced that the Biomedical Advanced Research and Development Authority (BARDA) of the U.S.

Acceleron Presents Preclinical Data for ACE-083 and ACE-2494 at the 20th International Annual Congress of the World Muscle Society

Acceleron Presents Preclinical Data for ACE-083 and ACE-2494 at the 20th International Annual Congress of the World Muscle Society

October 1, 2015

-- First presentation of data for new systemic muscle agent, ACE-2494, demonstrates substantial increases in muscle mass --

Joule Achieves U.S. EPA Registration for CO2-Recycled Ethanol

Joule Achieves U.S. EPA Registration for CO2-Recycled Ethanol

September 30, 2015

Bedford, Mass Joule, the pioneer of liquid fuels from recycled CO2, today announced that its fuel grade Sunflow®-E ethanol has been registered by the U.S. Environmental Protection Agency (EPA) for commercial use in E10 and E15 gasoline blends.